DelveInsight’s Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Pulmonary Arterial Hypertension (PAH) for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Pulmonary Arterial Hypertension (PAH) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Pulmonary Arterial Hypertension (PAH) till 2023.
Key Coverage and Benefits
• The report will help in developing business strategies by understanding the trends shaping and driving the global Pulmonary Arterial Hypertension (PAH) market.
• Identifying patient populations in the global Pulmonary Arterial Hypertension (PAH) market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension (PAH) therapeutics in each of the markets covered.
• To understand the future market competition in the global Pulmonary Arterial Hypertension (PAH) therapeutics market and Insightful review of the key market drivers and barriers.
Scope
• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2023.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023.
• It also provides Pulmonary Arterial Hypertension (PAH) for United States, EU5 and Japan from 2013 and forecasted Market to 2023.
Note: This report requires 7-10 business days to complete.
'
Table of Contents
• Pulmonary Arterial Hypertension (PAH) overview
• Pathophysiology
• Symptoms of disease
• Etiology of disease
• Diagnosis of disease
• Treatment of disease
• Overview of Marketed drugs
• Drug Description
• Mechanism of Action
• Pharmacokinetics Properties
• Marketed Details
• Patent Information
• Patent Exclusivity Expiry Assessment United States (US)
• Patents Details
• Historical and Forecasted sales of marketed molecules in the Global Pulmonary Arterial Hypertension (PAH) Market
• Global Epidemiology of Pulmonary Arterial Hypertension (PAH) Forecasted to 2023
• Global Market (2013-2015)
• Global Forecasted Market (2016-2023)
• Global Market by Geography
• Market of US (2013-2015)
• Forecasted Market of US (2016-2023)
• Market of Europe
• Market of Germany (2013-2015)
• Forecasted Market of Germany (2016-2023)
• Market of United Kingdom (2013-2015)
• Forecasted Market of United Kingdom (2016-2023)
• Market of France (2013-2015)
• Forecasted Market of France (2016-2023)
• Market of Italy (2013-2015)
• Forecasted Market of Italy (2016-2023)
• Market of Spain (2013-2015)
• Forecasted Market of Spain (2016-2023)
• Market of Japan (2013-2015)
• Forecasted Market of Japan (2016-2023)
• Market of ROW (2013-2015)
• Forecasted Market of ROW (2016-2023)
• Appendix
• Report Methodology
• Consulting Services
• Disclaimer
• Report Purchase Options
• About DelveInsight
List of Tables
• Table 1: Drug Description
• Table 2: Drug, Marketed Details United States (US)
• Table 3: Drug, Patent Number Specific Patent Expiry in US (Year), 2015
• Table 4: Drug, Patent Details for US
• Table 5: Pulmonary Arterial Hypertension (PAH) Drug Sales (USD Millions)
• Table 6: Global Epidemiology of Pulmonary Arterial Hypertension (PAH) (2013-2023)
• Table 7: Pulmonary Arterial Hypertension (PAH) Global Market (USD Millions), (2013-2015)
• Table 8: Pulmonary Arterial Hypertension (PAH) Global Market (USD Millions), (2016-2023)
• Table 9: Pulmonary Arterial Hypertension (PAH) US Market (USD Millions), (2013-2015)
• Table 10: Pulmonary Arterial Hypertension (PAH) US Market (USD Millions), (2016-2023)
• Table 11: Pulmonary Arterial Hypertension (PAH) Germany Market (USD Millions), (2013-2015)
• Table 12: Pulmonary Arterial Hypertension (PAH) Germany Market (USD Millions), (2016-2023)
• Table 13: Pulmonary Arterial Hypertension (PAH) United Kingdom Market (USD Millions), (2013-2015)
• Table 14: Pulmonary Arterial Hypertension (PAH) United Kingdom Market (USD Millions), (2016-2023)
• Table 15: Pulmonary Arterial Hypertension (PAH) France Market (USD Millions), (2013-2015)
• Table 16: Pulmonary Arterial Hypertension (PAH) France Market (USD Millions), (2016-2023)
• Table 17: Pulmonary Arterial Hypertension (PAH) Italy Market (USD Millions), (2013-2015)
• Table 18: Pulmonary Arterial Hypertension (PAH) Italy Market (USD Millions), (2016-2023)
• Table 19: Pulmonary Arterial Hypertension (PAH) Spain Market (USD Millions), (2013-2015)
• Table 20: Pulmonary Arterial Hypertension (PAH) Spain Market (USD Millions), (2016-2023)
• Table 21: Pulmonary Arterial Hypertension (PAH) Japan Market (USD Millions), (2013-2015)
• Table 22: Pulmonary Arterial Hypertension (PAH) Japan Market (USD Millions), (2016-2023)
• Table 23: Pulmonary Arterial Hypertension (PAH) ROW Market (USD Millions), (2013-2015)
• Table 24: Pulmonary Arterial Hypertension (PAH) ROW Market (USD Millions), (2016-2023)
List of Figures
• Figure 1: Pulmonary Arterial Hypertension (PAH) Drug Sales (USD Millions)
• Figure 2: Global Epidemiology of Pulmonary Arterial Hypertension (PAH) (2013-2023)
• Figure 3: Pulmonary Arterial Hypertension (PAH) Global Market (USD Millions), (2013-2015)
• Figure 4: Pulmonary Arterial Hypertension (PAH) Global Market (USD Millions), (2016-2023)
• Figure 5: Pulmonary Arterial Hypertension (PAH) US Market (USD Millions), (2013-2015)
• Figure 6: Pulmonary Arterial Hypertension (PAH) US Market (USD Millions), (2016-2023)
• Figure 7: Pulmonary Arterial Hypertension (PAH) Germany Market (USD Millions), (2013-2015)
• Figure 8: Pulmonary Arterial Hypertension (PAH) Germany Market (USD Millions), (2016-2023)
• Figure 9: Pulmonary Arterial Hypertension (PAH) United Kingdom Market (USD Millions), (2013-2015)
• Figure 10: Pulmonary Arterial Hypertension (PAH) United Kingdom Market (USD Millions), (2016-2023)
• Figure 11: Pulmonary Arterial Hypertension (PAH) France Market (USD Millions), (2013-2015)
• Figure 12: Pulmonary Arterial Hypertension (PAH) France Market (USD Millions), (2016-2023)
• Figure 13: Pulmonary Arterial Hypertension (PAH) Italy Market (USD Millions), (2013-2015)
• Figure 14: Pulmonary Arterial Hypertension (PAH) Italy Market (USD Millions), (2016-2023)
• Figure 15: Pulmonary Arterial Hypertension (PAH) Spain Market (USD Millions), (2013-2015)
• Figure 16: Pulmonary Arterial Hypertension (PAH) Spain Market (USD Millions), (2016-2023)
• Figure 17: Pulmonary Arterial Hypertension (PAH) Japan Market (USD Millions), (2013-2015)
• Figure 18: Pulmonary Arterial Hypertension (PAH) Japan Market (USD Millions), (2015-2023)
• Figure 19: Pulmonary Arterial Hypertension (PAH) ROW Market (USD Millions), (2013-2015)
• Figure 20: Pulmonary Arterial Hypertension (PAH) ROW Market (USD Millions), (2016-2023)
• Arena Pharmaceuticals
• Reviva Pharmaceuticals
• GlaxoSmithKline
• Selten Pharma
• Nippon Kayaku
• Gilead Sciences
• Abbott GmbH & Co. KG
